NCT03797170

Design of New Personalized Therapeutic Approaches for Diffuse Large B-cell Lymphoma

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 50 (actual)
• Sponsor: University of Bologna · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

In Europe diffuse large B-cell lymphoma (DLBCL) is a rare disease whereas in Italy it is not. Approximately 40% of DLBCL patients has refractory disease or will relapse after initial response. In onco-hematology, a role for gut microbiota (GM) in mediating immune activation in response to chemotherapy, has been suggested. In this scenario, the Investigators hypothesized that GM could play an important role in DLBCL prognosis and response to treatment, establishing a connection between lifestyle and clinical response. The project is aimed to the study of the functional GM layout in association with specific patterns of treatment response in de novo DLBCL undergoing standard first line chemo-immunotherapy. Results may build the scientific basis to design new and personalized intervention strategies (both in treatment approach and in life-style recommendations), to enhance clinical response and reduction of disease refractoriness through modulation of the gut microbial ecosystem.

Conditions

• Diffuse Large B Cell Lymphoma

Interventions

Type	Name	Description
OTHER	Gut microbiota samples	Gut microbiota analysis from diagnosis to follow up after first line-chemo-immuntherapy

Timeline

• Start date: 2019-04-02
• Primary completion: 2023-07-20
• Completion: 2023-12-20
• First posted: 2019-01-09
• Last updated: 2023-02-08

Locations

2 sites across 1 country: Italy